Norway
Key Contact
Christian von Plessen, PhD, Head of Lung cancer section, Dep of Pulmonary Medicine, Haukeland University Hospital, 5021 Bergen, Norway, Tel 0047 55972946, cell: 0047 97662551, christian.von.plessen@helse-bergen.no
Introduction
Christian is an internist and pulmonlogjst at Haukeland University Hospital in bergen, Norway. He is the head of the Lung cancer section at the department of pulmonary medicine. Christian recently defended his PhD thesis Improving the quality of chemotherapy for patients with advanced non-small cell lung cancer. His main interests in the field of quality improvement are clinical microsystems, patient flow, palliative respiratory care, comprehensive approaches to system wide improvements.
Units applying Clinical Microsystem Framework
COPD and Lung Cancer
Presentations
Quality Improvement
10.06.2004
Kliniske mikrosystemer. Mikro- og makroperspektiv - anvendelse av konseptet ved Lungeavdelingen Haukeland Universitetssykehus. Foredrag med avdelingsdirektor Alf H. Andreassen ved kurset "Helseledelse" arrangert av Senter for Videre- og etterutdanning, Universitetet i Bergen
04.11.2004
Initiating quality projects and making change in Norwegian health care. My experience of quality projects (do's and dont's advice) and my reflections on improvement changes - why some worked and some did not. Foredrag med avdelingsdirektor Alf H. Andreassen ved kurset "Quality and safety improvement in health care" for helsepersonell, Senter for Videre- og etterutdanning, Universitetet i Bergen
02.03.2005
Exploring your clinical microsystem with a new lens. Seminar om kliniske mikrosystemer med Professor Paul Batalden og Goran Henriks, European Microsystems Festival, Joenkoeping, Sverige
19.04.2005
Exploring your clinical microsystem with a new lens. Seminar om kliniske mikrosystemer med Professor Paul Batalden og Goeran Henriks pa European Forum on Quality Improvement in Health Care London
02.09.2005
Effektivitet pa Lungeavdelingen post 3. Finseseminar. Finse
06.09.2005
Samhandling som grunnlag for resultater. Lederutviklingsprogram Helse Bergen
20.9.2005
Mikrosystem - lose problemer der de oppstar. Sammen med avdelingsdirektor Alf Andreassen ved Helsedirektoratets konferanse Nasjonal konferanse for kvalitetsforbedring i sosial- og helsetjenesten, Oslo
28.10.2005
Kliniske Mikrosystemer - et praktisk verktoy i kvalitetsforbedring. Eksempler fra Lungeavdelingen, Norsk Forening for Lungemedisin, Oslo
01.04.2006
Arbeidsplassen i et systemperspektiv. Temadag Kvinneklinikken, Ullensvang
14.06.2006
Mikrosystemtenkningen skaper verdi for pasienten. Erfaringer fra Helse Bergen, Ringerikskonferansen, Ringerike
07.11.2006
Lindring al dyspnoe. Kurs i palliasjon, samarbeid mellom Bergen kommune og Haukeland Universitetssykehus
01.03.2007
Utvikling av kliniske mikrosystem. Mikrosystemfestivalen, Joenkoeping, Sverige
14.03.2007
Clinical mikrosystems. Med Goeran Henriks og Holger Kunz, Hauptstadt Kongress Anesthaesie, Berlin, Tyskland
15.09.2007
Hvorfor tar man rontgen for blodprovene? Kvalitetsdagen, HUS, Bergen
30.09.2007
Klinisk Mikrosystem og Pusterom, eksempel av et klinisk mikrosystem. Nasjonal konferanse for kvalitetsforbedring i sosial- og helsetjenesten, Oslo
22.11.2007
Palliativt klinisk mikrosystem pa Lungeavdelingen. Haukeland Universitetssykehus, Onkologisk forum, Oslo
27.03.2008
From cure to care, breathing zone a palliative clinical microsystem. 5. Clinical Microsystem Festival, Joenkoeping, Sverige
05.03.2009
Using microsystems to reduce anonymity in a hospital department. Med Ulla Olgaard, Center for Kvalitet, Region Syddanmark. 6. Clinical Microsystem Festival, Joenkoeping, Sverige
11.03.2009
Planlegging og gjennomforing av klinisk forbedringsarbeid ved lungeavdelingen, Haukeland universitetssykehus HF, basert pa mikrosystemtenkning og tilrettelagt for publisering. NFKH konferanse Oslo.
Medical Lectures
17.11.2005
Kvalitetsindikatorer i behandlingen av lungekreftpasienter ved Haukeland sykehus/Lungekreftpoliklinikken. Onkolgisk Forum, Tromso
23.01.2007
From cure to care. Lungerehabliteringskonferansen, Oslo
28.04.2007
We can afford third line treatment in lung cancer, contra. Nordic Lung Congress, Uppsala, Sweden
12.11.2007
Tungpust - Hva kan PUSTEROM pa Lungeavdelingen tilby? og Fysioterapi ved dyspnoe. Med Anne Grethe Paulsberg, Legeforeningskurs i palliasjon, Bergen
17.06.2008
Dyspnoe. Palliativt Forum Bergen
03.11.2008
Effectiveness of third generation chemotherapy on the survival of patients with advanced non-small cell lung cancer - a national study. Behandlingsvariasjoner i lungekreftbehandlingen, Oslo
Publications
Peer reviewed papers
Plessen von, C, Grinde, O, Gulsvik, A. Cryptogenic fibrosing alveolitis in a Norwegian hospital district 1984-98. Lungeforum, 1999; 9 (suppl 11): 28
Plessen von, C, Grinde, O, Gulsvik, A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003. 97: 428-35.
Plessen von C, Aslaksen A. Improving the quality of palliative care for ambulatory patients with lung cancer. BMJ 2005; 330(7503):1309-1313.
Plessen von C, Bergman B, Andresen O. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 2006; 95(8):966-973.
Helbekkmo N, Sundtrom S, Aaseboe U, Brunsvig PF, Plessen von C, Bremnes RM. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 2007 Aug 6;97(3):283-9.
Plessen von C, Strand TE, Wentzel-Larsen T--, Omenaas E, Wilking N, Soerenson S. Survival of patients with advanced non-small cell lung cancer before and after the general introduction of palliative chemotherapy in Norway - a population based study. Thorax 2008 Apr 4 [Epub ahead of print].
Helbekkmo N, Aasebo U, Sundstrom SH, von Plessen C, Brunsvig PF, Bremnes RM; for the Norwegian Lung Cancer Study Group. Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer. 2008 Apr 14. [Epub ahead of print]
Gronberg, H, Bremnes RM, Aasebo U, Brunsvig PF, Flotten, O, Amundsen, T, von Plessen C, Wang, M, Sundstrom SH for the Norwegian Lung Cancer Study Group. A prospective phase II study: High-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer 2008. Jun 5 [Epub ahead of print]
Abstracts
Plessen von, C, Grinde, O, Gulsvik, A. Cryptogenic fibrosing alveolitis in Bergen Hospital district 1984-98. Eur Resp J, 1999; 14 (suppl 30): 342s.
Plessen von, C, Grinde, O, Gulsvik, A. The occurence of diagnostic criteria for cryptogenic fibrosing alveolitis in patients with pulmonary fibrosis without known causes. A population based study. Eur Resp J, 2000; 16 (suppl 31): 116-7s
Grinde, O, Plessen von, C, Gulsvik, A. Inter- and Intraphysician reproducibility in the coding of files of patients with cryptogenic fibrosing alveolitis and related diagnoses. Eur Resp J, 2000; 16 (suppl 31): 116s
Plessen von, C, Grinde, O, Gulsvik, A. Incidence and prevalence of cryptogenic fibrosing alveolitis. J Resp Crit Care Med 2000; 161 (3), A49
Plessen von C, Strand TE, Wentzel-Larsen T, Omenaas E, Wilking N, Aasebo, U, Bremnes R, Soerenson S. Survival of patients with advanced non-small cell lung cancer before and after the general introduction of palliative chemotherapy in Norway - a population based study. JTO 2007 Sept 2(8) Suppl 4:S458.
Other publications
Plessen von, C. 1996. Krankheitserfahrungen von krebskranken Kindern und ihren Familien. 1996. Dissertasjon. Universitet Witten/Herdecke, Tyskland, Haensel-Hohenhausen, ISBN 3-8267-2394-5
Bremnes RM, Plessen von C, Sundstrom S. [Lung cancer--of more current interest than before]. Tidsskr Nor Laegeforen 2006; 126(15):1940.
Plessen von C. Palliativ kjemoterapi ved lungekreft kan begrenses Tidsskr Nor Laegeforen 127: 559. 2007
Accepted manuscripts
A randomized phase III study by the Norwegian Lung Cancer Study Group: Pemetrexed plus carboplatin versus gemcitabine plus carboplatin as first line chemotherapy in advanced non-small cell lung cancer. Bjorn H. Gronberg BH, Bremnes Rm, Flotten O, Amundsen T, Brunsvig PF, Hjelde H, von Plessen C, Stornes F, Tollali T, Wammer F, Aasebo U, Sundstrom S. on behalf of the Norwegian Lung Cancer Study Group. Akseptert i Journal of Clinical Oncology
Ad hoc referee
Journal of the Royal Society of Medicine, Age and Aging, British Medical Journal, Norwegian Journal of Epidemiology.